Adamas Pharmaceuticals (ADMS) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Join SI Premium – FREE
Adamas Pharmaceuticals (NASDAQ: ADMS) reported Q4 EPS of ($0.69), $0.05 better than the analyst estimate of ($0.74).
For earnings history and earnings-related data on Adamas Pharmaceuticals (ADMS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Takeda Pharmaceutical Company Limited (TAK) Reports Q3 EPS of JPY308.00; offers guidance
- Luxfer Holdings plc (LXFR) Misses Q3 EPS by 8c
- ASE Technology Holding Co., Ltd (ASX) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
